Get the Stockscreener App
4.12
2.37%
-0.10
Diamedica Therapeutics Inc stock is traded at $4.12, with a volume of 203.95K.
It is down -2.37% in the last 24 hours and up +15.41% over the past month.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
See More
Previous Close:
$4.22
Open:
$4.16
24h Volume:
203.95K
Relative Volume:
0.81
Market Cap:
$176.68M
Revenue:
-
Net Income/Loss:
$-19.90M
P/E Ratio:
-7.7736
EPS:
-0.53
Net Cash Flow:
$-19.80M
1W Performance:
-18.42%
1M Performance:
+15.41%
6M Performance:
-28.47%
1Y Performance:
+19.42%
1-Day Range:
$4.0145
$4.17
1-Week Range:
$4.0145
$5.60
52-Week Range:
$3.19
$6.8184
Diamedica Therapeutics Inc Stock (DMAC) Company Profile
Name
Diamedica Therapeutics Inc
Sector
Industry
Phone
(763) 496-5454
Address
301 CARLSON PARKWAY, MINNEAPOLIS, MN
Compare DMAC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DMAC
Diamedica Therapeutics Inc
|
4.12 | 217.29M | 0 | -19.90M | -19.80M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-24 | Initiated | H.C. Wainwright | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Jun-22-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-09-21 | Initiated | Oppenheimer | Outperform |
| Feb-17-21 | Initiated | ROTH Capital | Buy |
| Oct-30-20 | Initiated | Guggenheim | Buy |
| Jul-08-20 | Initiated | Maxim Group | Buy |
| Apr-30-19 | Initiated | Dougherty & Company | Buy |
| Mar-05-19 | Initiated | Lake Street | Buy |
View All
Diamedica Therapeutics Inc Stock (DMAC) Latest News
Is this a good reentry point in DiaMedica Therapeutics Inc.Buy Point Strategy with Profit Protection - Newser
What’s the recovery path for long term holders of DiaMedica Therapeutics Inc.Daily Market Momentum and Pressure Analysis - Newser
How volatile is DiaMedica Therapeutics Inc. stock compared to the marketExpert Picks Signals To Watch Now - jammulinksnews.com
Is DiaMedica Therapeutics Inc. stock overvalued or undervaluedRetirement Planning Forecasts For Consistent Profits - jammulinksnews.com
Can trapped investors hope for a rebound in DiaMedica Therapeutics Inc.Free AI Driven Stock Trend Forecast - Newser
Best data tools to analyze DiaMedica Therapeutics Inc. stockFree Long Hold Safe Return Strategy - Newser
Multi factor analysis applied to DiaMedica Therapeutics Inc.Intraday Price Action Forecast Planner - Newser
What makes DiaMedica Therapeutics Inc. stock price move sharplyBuy Zone Strategy with Pattern Recognition - Newser
Real time pattern detection on DiaMedica Therapeutics Inc. stockReal Chart Based Opportunity Identification - Newser
Can momentum traders help lift DiaMedica Therapeutics Inc.Portfolio Review Summary with Five-Year Outlook - Newser
Should I hold or sell DiaMedica Therapeutics Inc. stock in 2025Swing Trade Tips For Consistent Profits - jammulinksnews.com
Analyzing DiaMedica Therapeutics Inc. with risk reward ratio chartsFree Accurate Buy Point for Momentum Stocks - Newser
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Shares Could Be 25% Below Their Intrinsic Value Estimate - 富途牛牛
Volume spikes in DiaMedica Therapeutics Inc. stock – what they meanDaily Technical Forecast for Quick Gains - Newser
How DiaMedica Therapeutics Inc. stock performs during market volatilityStock Market Watch with Smart Filters - Newser
DiaMedica Therapeutics Inc. Stock Support and Resistance Levels You Should KnowLow Risk Strategy with Smart Entry Zones - Newser
Off-market insider buying at DiaMedica Therapeutics (DMA) - The Globe and Mail
Quant Models Detect Momentum Reversal in DiaMedica Therapeutics Inc.Fast Entry High Potential Stock Alerts Triggered - metal.it
Published on: 2025-07-29 04:31:05 - metal.it
Is DiaMedica Therapeutics Inc. Stock a Smart Buy in 2025 Investment Analysis InsideReversal Alert Based on RSI Indicator Confirmed - metal.it
Diamedica Stock Soars 10.2% on Major Shareholder's Purchase - AInvest
Analyzing DiaMedica Therapeutics Inc. with risk reward ratio charts Intraday Price Action Forecast Planner - Newser
What is the risk reward ratio of investing in DiaMedica Therapeutics Inc. stockBuild wealth with high-performing stocks - jammulinksnews.com
What are the latest earnings results for DiaMedica Therapeutics Inc.Explosive trading opportunities - jammulinksnews.com
What are analysts’ price targets for DiaMedica Therapeutics Inc. in the next 12 monthsOutstanding investment returns - jammulinksnews.com
What are the technical indicators suggesting about DiaMedica Therapeutics Inc.Rapid growth opportunities - jammulinksnews.com
How does DiaMedica Therapeutics Inc. compare to its industry peersLightning-fast growth - jammulinksnews.com
Intrinsic Value of DiaMedica Therapeutics Inc. Stock: Is It Undervalued or OvervaluedSafer Investing With Bigger Upside - Newser
DiaMedica therapeutics (DMAC): Trill AB buys $5.4m in shares By Investing.com - Investing.com South Africa
DiaMedica therapeutics (DMAC): Trill AB buys $5.4m in shares - Investing.com
DiaMedica therapeutics (DMAC) shareholder TomEnterprise Private AB buys $10M in stock - Investing.com
DiaMedica Therapeutics Stock (DMAC) Opinions on $30 Million Private Placement - Quiver Quantitative
Ischemic Stroke Pipeline Experiences Rapid Expansion As Over 50+ Leading Companies Advance Novel Therapies - Menafn.com
What drives DiaMedica Therapeutics Inc. stock priceRapidly growing investment returns - PrintWeekIndia
Ischemic Stroke Pipeline Experiences Rapid Expansion as Over 50+ Leading Companies Advance Novel Therapies - The Globe and Mail
DiaMedica gains on positive mid-stage trial data for lead drug in preeclampsia - MSN
DiaMedica Therapeutics Inc. Stock Analysis and ForecastFree Market Volatility Navigation Tips - PrintWeekIndia
Diamedica Therapeutics Inc Stock (DMAC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Diamedica Therapeutics Inc Stock (DMAC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Von Koch Thomas | 10% Owner |
Jul 23 '25 |
Buy |
3.50 |
2,857,142 |
9,999,997 |
8,383,577 |
| JACINTO RICHARD II | 10% Owner |
Jul 23 '25 |
Buy |
3.50 |
400,000 |
1,400,000 |
4,958,823 |
| Pilnik Richard D. | Director |
Apr 07 '25 |
Option Exercise |
2.11 |
24,000 |
50,640 |
312,995 |
| Giuffre Randall Michael | Director |
Feb 13 '25 |
Option Exercise |
2.56 |
17,000 |
43,570 |
392,412 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):